<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82532">
  <stage>Registered</stage>
  <submitdate>15/01/2008</submitdate>
  <approvaldate>18/01/2008</approvaldate>
  <actrnumber>ACTRN12608000029392</actrnumber>
  <trial_identification>
    <studytitle>Mirena Intra-Uterine System: Does it Improve Long Term Symptoms in Women with Chronic Pelvic Pain and/or Endometriosis after Laparoscopy?</studytitle>
    <scientifictitle>Mirena Intra-Uterine System: Does it Improve Long Term Symptoms in Women with Chronic Pelvic Pain and/or Endometriosis after Laparoscopy?
 
A multicentre randomized placebo-controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Pelvic Pain in women in reproductive age</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Contraception</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Contraception</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Mirena is a levonorgestrel-releasing intrauterine system, which consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir. The reservoir consists of a cylinder, made of a mixture of levonorgestrel and silicone containing a total of 52 mg levonorgestrel. Low doses of levonorgestrel can be administered into the uterine cavity with the MIRENA intrauterine delivery system. Initially, levonorgestrel is released at a rate of approximately 20 Âµg/day. This rate decreases progressively to half that value after 5 years.</interventions>
    <comparator>Placebo Intrauterine System Insertion, is the inactive form of the intrauterine system. It contain empty reservoir, thus no hormone included.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Other interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Daily ratings (NRS) of dysmenorrhoea</outcome>
      <timepoint>01/02/2008 till 01/02/2010</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Daily ratings using numerical rating scale (NRS) of pelvic pain</outcome>
      <timepoint>01/02/2008 till 01/02/2010</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Use of rescue analgesia/therapies including an NRS before use and a record of the indication</outcome>
      <timepoint>01/02/2008 till 01/02/2010</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life using Endometriosis Health Profile (EHP)-30 with separate and total scores</outcome>
      <timepoint>01/02/2008 till 01/02/2010</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Study specific adverse event questionnaires with direct questions and free text administered at the same time points as the EHP-30</outcome>
      <timepoint>01/02/2008 till 01/02/2010</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All women with pelvic pain and or dysmenorrhoea</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Acute pelvic inflammatory disease (PID) and or positive swab for Chlamydia +/- Gonorrhea 
2. Chronic PID as defined by the presence of tubal damage (hydrosalpinx, hydrosalpinges) noted at surgery
3. Breast feeding women 
4. Positive pregnancy urinary test or plan for a pregnancy within 12 months after enrollment
5. Previous hysterectomy
6. Contraindications to laparoscopy and/or anesthesia
7. Contraindication to the use of IUS according to WHO criteria
8. Hormonal treatment within the last three months
9. Malignancies
10. Known ovarian cysts other than endometriotic
10. Intention to use other medical treatment that may affect pelvic pain scores within 12 month 
11. Use of hormonal treatments in the last three months prior to trial recruitment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The study centers will be provided with individually sealed packages containing the treatment for each patient.</concealment>
    <sequence>Computer-generated list.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/10/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2750</postcode>
    <postcode>2148</postcode>
    <postcode>2145</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>Early Pregnancy, Gynaecological Ultrasound and Advanced Endoscopic Unit
Nepean Centre for Perinatal Care  
Nepean Clinical School. 
Nepean Hospital
Penrith 2750, NSW</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Sydney</fundingname>
      <fundingaddress>Early Pregnancy, Gynaecological Ultrasound and Advanced Endoscopic Unit
Nepean Centre for Perinatal Care  
Nepean Clinical School. 
Nepean Hospital
Penrith 2750, NSW</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Nepean Hospital</sponsorname>
      <sponsoraddress>Early Pregnancy, Gynaecological Ultrasound and Advanced Endoscopic Unit
Nepean Centre for Perinatal Care  
Nepean Clinical School. 
Nepean Hospital
Penrith 2750, NSW</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>New secondary sponsor name. Please modify.</sponsorname>
      <sponsoraddress>New secondary sponsor address. Please modify.</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>New secondary sponsor name. Please modify.</sponsorname>
      <sponsoraddress>New secondary sponsor address. Please modify.</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The null hypothesis is: Women with pelvic pain and or dysmenorrhoea who undergo laparoscopy and insertion of Mirena IUS will have a reduction in symptoms of at least 50% at 12 months follow-up (primary point).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney West Area Health Service Human Researche Ethics Committee, Nepean Campus</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>16/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>16/01/2008</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>George Condous</name>
      <address>Early Pregnancy, Gynaecological Ultrasound and Advanced Endoscopic Unit
Nepean Centre for Perinatal Care  
Nepean Clinical School. 
Nepean Hospital
Penrith 2750, NSW</address>
      <phone>(02) 4734 2000</phone>
      <fax />
      <email>gcondous@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>George Condous</name>
      <address>Early Pregnancy, Gynaecological Ultrasound and Advanced Endoscopic Unit
Nepean Centre for Perinatal Care  
Nepean Clinical School. 
Nepean Hospital
Penrith 2750, NSW</address>
      <phone>(02) 4734 2000</phone>
      <fax />
      <email>gcondous@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dalya Alhamdan</name>
      <address>Early Pregnancy, Gynaecological Ultrasound and Advanced Endoscopic Unit
Nepean Centre for Perinatal Care  
Nepean Clinical School. 
Nepean Hospital
Penrith 2750, NSW</address>
      <phone>0419556832</phone>
      <fax />
      <email>doctord972@yahoo.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>